Revolutionizing
Neurological Care with
AI-Driven Precision
AI-powered platform delivering real-time, personalized insights to optimize neurological treatment, improve patient recovery and reduce healthcare costs.
MyndLink
AI-Powered Intelligence for Transforming Neurological Treatment
The Problem
Up to 60-70% of stroke survivors experience persistent upper limb impairment1, 2 despite approximately 900,000 annual stroke cases across North America3. Similarly, 30%4, 5 of the 50,000+4 annual Spinal Cord Stimulator procedures fail, with 10-year per-patient costs — encompassing implantation, annual budget modeling, resulting in over $1 billion in annual waste from failed procedures. These parallel challenges in neurological care highlight the urgent need for AI-powered solutions that can predict treatment success and personalize patient care.
1 Parker J, Powell L, Mawson S. Effectiveness of Upper Limb Wearable Technology for Improving Activity and Participation in Adult Stroke Survivors: Systematic Review. J Med Internet Res. 2020;22(1):e15981. doi: 10.2196/15981. PMID: 31913131., 2 Pollock A, Farmer SE, Brady MC, et al. Interventions for improving upper limb function after stroke. Cochrane Database Syst Rev. 2014;(11):CD010820. doi: 10.1002/14651858.CD010820.pub2. PMID: 25387001., 3 Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149:e347–e913. doi: 10.1161/CIR.0000000000001209. AND Heart & Stroke Foundation of Canada. Stroke in Canada is on the rise [press release]. 2019. Available at: heartandstroke.ca., 4 Farber SH, Han JL, Elsamadicy AA, et al. Spinal cord stimulation failure: evaluation of factors underlying hardware explantation. J Neurosurg Spine. 2019;32(1):133–138. doi: 10.3171/2019.6.SPINE19505. PMID: 31585414., 5 Dougherty MC, Woodroffe RW, Wilson S, Gillies GT, Howard MA 3rd, Carnahan RM. Risk Factors and Survival Analysis of Spinal Cord Stimulator Explantation. Neuromodulation. 2021;24(1):61–67. doi: 10.1111/ner.13173. PMID: 32491256., 6 Kumar K, Bishop S. Financial impact of spinal cord stimulation on the healthcare budget: a comparative analysis of costs in Canada and the United States. J Neurosurg Spine. 2009;10(6):564–573. doi: 10.3171/2009.2.SPINE0865. PMID: 19558289.
The Solution
MyndTec is developing MyndLynk, an AI-powered solution that transforms neurological treatment by predicting outcomes, optimizing protocols, and automating clinical workflows. Designed to integrate seamlessly with MyndMove for stroke and spinal cord injury rehabilitation, MyndLink uses advanced predictive analytics and ambient listening to eliminate administrative burden, optimize treatment protocols in real-time, and generate the objective outcome data required for value-based care. The result: facilities increase revenue, patients achieve better recovery, and healthcare systems save billions.
MyndTec leverages over a decade of expertise in neurological care and regulatory success to drive AI innovations that transform outcomes and reduce costs.
MyndMove
Our First Product in Neurological Care
MyndMove™ is a non-invasive therapy designed to help patients with paralysis from stroke or spinal cord injury regain movement and improve quality of life. By using electrical signals, MyndMove stimulates the brain to form new neural connections, a process known as neuroplasticity, which aids in recovery and rebuilding strength. Clinical studies show significant improvements in movement and function, even when other treatments have not been effective. Authorized in both the U.S. and Canada, MyndMove offers personalized neuromodulation settings to enhance motor control and sensation.